Content
Summary
High-throughput screening (HTS) for drug combinations systematically identifies synergistic pairs to reduce toxicity and prevent resistance, particularly in cancer and infectious diseases. The workflow utilizes acoustic dispensing technology for non-contact compound transfer, integrating automated liquid handling and bioinformatics to process large-scale viability data.
Intuition
Think of HTS for drug combinations as a massive, automated matchmaking service for medicines. Instead of testing drugs one by one, we test thousands of pairs simultaneously to find those that work better together (synergy) than alone. The key innovation is acoustic dispensing, which uses sound waves to move liquids without touching them, preventing cross-contamination and saving resources. This allows researchers to screen hundreds of thousands of combinations quickly, using cell viability as the primary metric to see if the drug pair kills the target cells effectively.
Derivation
- Identify the goal: systematic identification of synergistic drug pairs.
- Select the method: High-throughput screening (HTS) using in vitro assays.
- Implement the technology: Use acoustic dispensing for non-contact, anywhere-to-anywhere transfer.
- Integrate automation: Combine automated liquid handlers, compound stores, and bioinformatics.
- Measure the outcome: Assess cell viability (e.g., via CellTiter-Glo) to determine synergy.
Worked example
A research team at NCATS needs to screen drug combinations for Ebola. They have DMSO stock solutions and need to dispense them into 1536-well plates for cell viability testing. How should they manage the workflow to minimize contamination and ensure accuracy?
- Store DMSO stock solutions at -20°C.
- Perform all subsequent operations at room temperature.
- Use acoustic dispensing technology to transfer compounds from source plates to intermediate and mother plates, and finally to the 1536-well assay plate.
- Ensure the use of polypropylene compound plates and cyclic olefin copolymer (COC) acoustic source plates for compatibility.
- Seed TC71 Ewing’s sarcoma or relevant Ebola cell lines in the assay plates.
- Add CellTiter-Glo reagent after treatment to measure luminescence as a proxy for cell viability.
- Process data using informatics tools to identify synergistic interactions.
Answer The team should use a fully automated workflow starting with -20°C stored DMSO stocks, employing acoustic dispensing for non-contact transfer into 1536-well plates, and measuring viability via CellTiter-Glo luminescence, followed by bioinformatics analysis.
Common mistakes
- Using traditional contact-based pipetting, which is more costly and prone to contamination.
- Performing all operations at -20°C; only stock solutions should be stored there, while subsequent steps occur at room temperature.
- Ignoring the need for specific consumables like COC acoustic source plates, which are required for acoustic dispensing compatibility.